The meaning of ALLHAT

Journal of Hypertension

Volumn 21, Issue 2, 2003, Pages 233-234

  Kaplan, Norman M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURESIS; DRUG EFFECT; DRUG SAFETY; EDITORIAL; HEART INFARCTION; HUMAN; HYPERTENSION; MEDICAL RESEARCH; PRIORITY JOURNAL;

EID: 0037331698     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200302000-00004     Document Type: Editorial

References (9)

1. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
2. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997; 277:739-745.
3. Blood Pressure Lowering Treatment Trialists' Collaboration. Effect of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355:1955-1964.
4. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension. Lancet 1998; 351:1755-1762.
5. Kaplan NM. Kaplan's Clinical hypertension, 8th edn. Philadelphia: Lippincott Williams & Wilkins; 2002. pp. 237-338.
6. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326-1331.
7. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691.
8. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
9. Jafar TH, Schmid CH, Landa M, Giatris I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of non-diabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001; 135:73-87.